Brian Vastag on Nostr: Akiko Iwasaki at Yale will be studying many immune markers in these patients (Proal ...
Akiko Iwasaki at Yale will be studying many immune markers in these patients (Proal says she is very excited about this).
Our goal is better understanding who might respond to rapamycin and refine inclusion criteria for a larger trial. So it's a pilot trial. No data yet.
Published at
2024-11-08 21:59:16Event JSON
{
"id": "0c0bbfa2adf09ea61bbf6cf10ff500b263f5938105b7ef521dda0eefaffac152",
"pubkey": "c69a32960f5b587616a11783e4a8aeee5f8b1e067fe4a16f05194ff3f2ff1271",
"created_at": 1731103156,
"kind": 1,
"tags": [
[
"e",
"bd27280d942bf058b5b85745d2cb561b6c8cd075557cdaea962cc010a81db2ea",
"wss://relay.mostr.pub",
"reply"
],
[
"proxy",
"https://sciencemastodon.com/users/brianvastag/statuses/113449576476323869",
"activitypub"
]
],
"content": "Akiko Iwasaki at Yale will be studying many immune markers in these patients (Proal says she is very excited about this). \n\nOur goal is better understanding who might respond to rapamycin and refine inclusion criteria for a larger trial. So it's a pilot trial. No data yet.",
"sig": "36db43f0c191529c6e20ba0ed04433564ae2c3569804a7a204d87c1969e71176f48a39f1c0ce9f2bd9938976d8eeb77c5ee1b55a0f594979a70a7f478fa289e1"
}
